Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors: Pilot study

Diagnostic Pathology

Volumn 2, Issue 1, 2007, Pages

  Abd El All, Howayda ^a,b  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b MINISTRY OF HEALTH   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247895438     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-2-9     Document Type: Article

References (34)

1. Abd El All : Aberrant expression of smooth muscle actin and s100p on diffuse large B cell lymphoma: A case report of an orbital DLBCL. In XIII Meeting of the European Association of Hematopatjhology Vienna, Autria; 2006. Abstract 34.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Losses IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Arrnitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillerrno A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-Cell lymphoma. NEJM 2002, 346:1937-1947.
4. Jaffe ES, Harris NL, Vardiman JW: Pathology and Genetics. Tumors of hematopoietic and lymphoid tissues. WHO Classification of Tumors 2001.
5. Pileri SA, Dirnhofer S, Went Ph, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B, Zinzani PL: Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002, 41:482-509.
6. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A: Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005, 106:3183-3190.
7. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
8. Berglund M, Thunberg U, Amini RA, Book M, Roos G, Erlanson M, Linderoth J, Dictor M, Jerkeman M, Cavallin-Ståhl E, Sundström C, Rehn-Erikssön S, Backlin C, Hagberg H, Rosenquist R, Enblad G: Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Potho/2005, 18:1113-1120.
9. Biasoli I, Morais JC, Scheliga A, Milito CB, Romano S, Land M, Pulcheri W, Spector N: CD 10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopathology 2005, 46:328-333.
10. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Campo E, Ott G, Müller-Hermelink HK, Delabie J, Jaffe ES, Grogan TM, Connors JM, Vose JM, Armitage JO, Staudt LM, Chan WC: BCL2 expression is a prognostic marker for the activated B-Cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:961-968.
11. Miller TP, Grogan TM, Dahlber S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN: Prognostic significance of the Ki67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994, 83:1460-1466.
12. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, Pacini R, Alunni C, Natali-Tanci L, Ugolini B, Sebastiani C, Cattoretti G, Pileri S, Dalla-Favera R, Stein H: A monoclonal antibody (MUMIp) detects expression of the MUMI/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000, 95:2084-2092.
13. Dogan A, Bagdi E, Munson P, Isaacson PG: CD 10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am j Surg Pathol 2000, 24:846-852.
14. Falini B, Mason DY: Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002, 99:409-426.
15. Owen MJ, Auger J, Barber BH, Edwards AJ, Walsh FS, Crumpton MJ: Actin may be present on the lymphocyte surface. Proc Natl Acad Sci 1978, 75:4484-4488.
16. Mely-Goubert B, Philip PJ: Distribution of actin content in human B and T lymphocytes by DNAse I inhibition test. Immunol Lett 1983, 7:81-84.
17. Atkins H, Anderson PJ: Actin and tubulin of normal and leukaemic lymphocytes. Biochem J 1982, 207:535-539.
18. Stark R, Liebes LF, Nevrla D, Conklyn M, Silber R: Decreased actin content of lymphocytes from patients with chronic lymphocytic leukaemia. Blood 1982, 59:536-541.
19. Liebes LF, Stark R, Nevrla D, Grusky G, Zucker-Franklin D, Silber R: Purification and characterization of actin from normal and chronic lymphocytic leukemia lymphocytes. Cancer Res 1983, 43:4966-4973.
20. Melamed I, Downey GP, Aktories K, Roifman CM: Microfilament assembly is required for antigen-receptor-mediated activation of human B lymphocytes. J Immunol 1991, 147(4): 1139-1146.
21. Ohtsu M, Sakai N, Fujita H, Kashiwagi M, Gasa S, Shimizu S, Eguchi Y, Tsujimoto Y, Sakiyama Y, Kobayashi K, Kuzumaki N: Inhibition of apoptosis by the actin-regulatory protein gelsolin. EM60 J 1997, 16:4650-4656.
22. Olave IA, Reck-Peterson SL, Crabtree GR: Nuclear actin and actin-related proteins in chromatin remodeling. Annu Rev Biochem 2002, 71:755-781.
23. Zhu X, Zeng X, Huang B, Hao S: Actin is closely associated with RNA polymerase II and involved in activation of gene transcription. Biochem Biophys Res Commun 2004, 321:623-630.
24. Gettemans J, Van Impe K, Delanote V, Hubert T, Vandekerckhove J, De Corte V: Nuclear actin-binding proteins as modulators of gene transcription. Traffic 2005, 6:847-857.
25. Fung CHK, Antar S, Yonant T, Lo JW: Actin-positive spindle cell lymphoma. Arch Pathol Lab Med 1993, 117:1053-1055.
26. Wang J, Sun NC, Nozawa Y, Arber DA, Chu P, Chang KL, Weiss LM: Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features. Histopathology 2001, 39:476-481.
27. Takeshita H, Kusuzaki K, Ashihara T, Gebhardt MC, Mankin HJ, Hirasawa Y: Actin organization associated with the expression of multidrug resistant phenotype in osteosarcoma cells and the effect of actin depolymerization on drug resistance. Cancer letters 1998, 126:75-81.
28. Takahashi K, Isobe T, Ohtsuki Y, Sonobe H, Yamaguchi H, Akagi T: S-100 protein positive human T-lymphocyte. Am J Clin Patbol 1985, 83:69-72.
29. Ruco LP, Stoppacciaro A, Barsotti P, Vitolo D, Mirolo M, Cassano AM, Guglielmi C, Mandelli F, Uccini S, Baroni CD: S-100+ lymph node neoplasm. Report of a case with histological AL and immunological features intermediate between T cell lymphoma and malignant histiocytosis. Virch Arch 1984, 404:351-358.
30. Chan JK, Ng CS, Chu YC, Wong KF: S-100 protein-positive sinusoidal large cell lymphoma. Hum Pathol 1987, 18:756-759.
31. Hanson CA, Bockenstedt PL, Schnitzer B, Fox DA, Kueck B, Braun DK: S100-positive, T-cell chronic lymphoroliferative disease: an aggressive disorder of an uncommon T-cell subset. Blood 1991, 78:1803-1813.
32. Dong J, Chong YY, Meyerson HJ: Hepatosplenic alpha beta T-cell lymphoma: a report of an S100-positive case. Arch Pathol Lab Med 2003, 127:19-122.
33. Chan JKC, Sin VC, Wong KF, Ng CS, Tsang WYW, Chan CH, Cheung MMC, Lau WH: Nonnasal Lymphoma Expressing the Natural Killer Cell Marker CD56: A clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997, 89:4501-4513.
34. Jassern E, Serkies K, Dziadziuszko R, Drozdowska A, Kobierska-Gulida G, Skokowski J, Góźdź S, Urbaniak A, Sygut J, Jassem J: Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer. Biomorkers 2006, 11:262-269.